ondansetron has been researched along with citalopram in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Bang-Andersen, B; Frederiksen, K; Hogg, S; Jensen, KG; Jørgensen, M; Mørk, A; Nielsen, SM; Ruhland, T; Smith, G; Stensbøl, TB; Zhong, H | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Meert, TF | 1 |
| Bourin, M; Redrobe, JP | 1 |
| De Deurwaerdère, P; Moison, D; Porras, G; Spampinato, U | 1 |
| Kwon, P; Lefkowitz, W | 1 |
| Bang-Andersen, B; Boyle, NJ; Brennum, LT; Bundgaard, C; Fischer, CW; Hogg, S; Lassen, AB; Liebenberg, N; Miller, S; Mørk, A; Nielsen, SM; Pehrson, A; Sánchez, C; Stensbøl, TB; Wegener, G; Westrich, L; Zhong, H | 1 |
| Burger, DM; van Herpen, CML; Verwimp-Hoeks, MPA | 1 |
| Flury, G; Neumeier, C; Thaler, S | 1 |
| Kurhe, Y; Mahesh, R | 1 |
| Addula, M; Kolli, V | 1 |
| Naguy, A | 1 |
1 review(s) available for ondansetron and citalopram
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
23 other study(ies) available for ondansetron and citalopram
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Topics: Animals; Antidepressive Agents; Cell Line; Depressive Disorder, Major; Drug Partial Agonism; Drug Stability; Hippocampus; Humans; In Vitro Techniques; Microsomes, Liver; Oocytes; Piperazines; Radioligand Assay; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Receptors, Serotonin, 5-HT3; Recombinant Proteins; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Sulfides; Vortioxetine; Xenopus | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relationship, Drug; Drinking; Fluoxetine; Male; Ondansetron; Rats; Receptors, Serotonin; Ritanserin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists | 1993 |
Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test.
Topics: Amphetamines; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Desipramine; Drug Interactions; Fluoxetine; Fluvoxamine; Imipramine; Ketanserin; Male; Maprotiline; Mice; Ondansetron; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Ritanserin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Swimming | 1997 |
Conditional involvement of striatal serotonin3 receptors in the control of in vivo dopamine outflow in the rat striatum.
Topics: Amphetamine; Analgesics, Opioid; Animals; Brain Chemistry; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Citalopram; Cocaine; Corpus Striatum; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Interactions; Electrochemistry; Haloperidol; Male; Microdialysis; Morphine; Ondansetron; Rats; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT3; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT3 Receptor Antagonists; Tropanes | 2003 |
Neonatal extrapyramidal movements. Neonatal withdrawal due to maternal citalopram and ondansetron use.
Topics: Adult; Anti-Anxiety Agents; Basal Ganglia Diseases; Citalopram; Female; Humans; Infant, Newborn; Lorazepam; Maternal Welfare; Ondansetron; Phenobarbital; Pregnancy; Prenatal Exposure Delayed Effects; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2008 |
Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.
Topics: Animals; Anti-Anxiety Agents; Biogenic Monoamines; Citalopram; Depressive Disorder, Major; Humans; Male; Ondansetron; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Reflex; Serotonin Plasma Membrane Transport Proteins; Sulfides; Vocalization, Animal; Vortioxetine | 2012 |
Aprepitant quetiapine: a clinically significant drug interaction in a patient treated for head and neck cancer.
Topics: Adult; Antidepressive Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Carcinoma; Chemoradiotherapy; Cisplatin; Citalopram; Depression; Dexamethasone; Dibenzothiazepines; Drug Interactions; Humans; Laryngeal Neoplasms; Male; Morpholines; Ondansetron; Quetiapine Fumarate | 2012 |
[Drug-induced malignant arrhythmias. IT prevents lethal drug mixtures].
Topics: Adult; Analgesics, Opioid; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Decision Support Systems, Clinical; Drug Therapy, Combination; Drug Therapy, Computer-Assisted; Humans; Male; Medical Order Entry Systems; Methadone; Ondansetron; Torsades de Pointes | 2013 |
Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.
Topics: Animals; Anxiety; Behavior, Animal; Body Weight; Brain; Citalopram; Corticosterone; Depression; Diet, High-Fat; Glucose Tolerance Test; Glutathione; Insulin; Leptin; Male; Malondialdehyde; Mice; Mice, Obese; Obesity; Ondansetron; Oxidative Stress; Serotonin; Synaptic Transmission | 2015 |
Ondansetron-Induced Myoclonus With Escitalopram and HAART: Role of Drug Interactions.
Topics: Adult; Anti-Anxiety Agents; Antiretroviral Therapy, Highly Active; Anxiety Disorders; Citalopram; Drug Interactions; HIV Infections; Humans; Male; Myoclonus; Ondansetron; Selective Serotonin Reuptake Inhibitors | 2019 |
Ondansetron-Induced Myoclonus With Escitalopram and Highly Active Antiretroviral Therapy: A Closer Look at 5-HT3 Receptors.
Topics: Antiretroviral Therapy, Highly Active; Citalopram; Drug Interactions; Humans; Myoclonus; Ondansetron; Receptors, Serotonin, 5-HT3 | 2020 |